Table 2.
Baseline characteristics according to the primary endpoint
| Variable | No such events (n = 866) | Primary endpoint (n = 548) | P-value |
|---|---|---|---|
| Demographics | |||
| Age (years) | 58.21 ± 9.35 | 57.76 ± 9.31 | 0.374 |
| Male sex, n (%) | 668 (77.14) | 435 (79.38) | 0.354 |
| BMI (kg/m2) | 25.64 (23.80, 27.64) | 25.95 (24.22, 28.29) | 0.004 |
| Risk factors | |||
| Cigarette smoking, n (%) | 521 (60.16) | 337 (61.50) | 0.657 |
| Diabetes, n (%) | 329 (37.99) | 268 (48.91) | < 0.001 |
| Hypertension, n (%) | 550 (63.51) | 356 (64.96) | 0.619 |
| Dyslipidemia, n (%) | 864 (99.77) | 546 (99.64) | 1 |
| Previous MI, n (%) | 104 (12.01) | 103 (18.80) | 0.001 |
| Previous stroke, n (%) | 96 (11.09) | 65 (11.86) | 0.718 |
| Previous PCI, n (%) | 198 (22.86) | 198 (36.13) | < 0.001 |
| PAD, n (%) | 120 (13.86) | 74 (13.50) | 0.913 |
| Family history of CAD, n (%) | 168 (19.40) | 92 (16.79) | 0.244 |
| Clinical presentations | |||
| Multi-vessel CAD, n (%) | 652 (75.29) | 488 (89.05) | < 0.001 |
| LVEF (%) | 64 (61, 66) | 64 (60, 66) | 0.010 |
| Laboratory measurements | |||
| TC (mmol/L) | 4.02 ± 1.03 | 4.10 ± 1.06 | 0.159 |
| LDL-C (mmol/L) | 2.38 ± 0.83 | 2.47 ± 0.88 | 0.049 |
| HDL-C (mmol/L) | 1.11 ± 0.30 | 1.07 ± 0.29 | 0.003 |
| Triglycerides (mmol/L) | 1.71 ± 1.22 | 1.82 ± 1.20 | 0.129 |
| FPG (mmol/L) | 6.09 ± 1.93 | 6.57 ± 2.39 | < 0.001 |
| HbA1c (%) | 6.24 ± 1.06 | 6.60 ± 1.36 | < 0.001 |
| Pcr (μmol/L) | 81.24 ± 15.59 | 82.11 ± 20.79 | 0.370 |
| eGFR (mL/min per 1.73 m2) | 110.43 (97.32, 123.70) | 111.88 (95.43, 128.43) | 0.309 |
| NT-proBNP (pg/mL) | 156.03 ± 329.01 | 181.99 ± 343.80 | 0.156 |
| hs-CRP (mg/L) | 3.83 ± 5.01 | 4.40 ± 7.15 | 0.079 |
| Medications at discharge | |||
| DAPT, n (%) | 859 (99.19) | 545 (99.45) | 0.807 |
| Statins, n (%) | 849 (98.04) | 537 (97.99) | 1.000 |
| Dual-lipid lowering therapy, n (%) | 36 (4.16) | 26 (4.74) | 0.695 |
| ACEI/ARBs, n (%) | 414 (47.81) | 293 (53.47) | 0.043 |
| β-Blockers | 697 (80.48) | 486 (88.69) | 0.0001 |
| Insulin, n (%) | 69 (7.97) | 86 (15.69) | < 0.001 |
| Oral hypoglycemic drugs, n (%) | 202 (23.33) | 165 (30.11) | 0.006 |
| Angiographic findings | |||
| Restenotic lesions, n (%) | 29 (3.35) | 44 (8.03) | < 0.001 |
| Chronic total occlusions, n (%) | 94 (10.85) | 97 (17.70) | < 0.001 |
| Lesions > 20 mm long, n (%) | 588 (67.90) | 412 (75.18) | 0.004 |
| Number of stents | 2 (1, 2) | 2 (1, 3) | < 0.001 |
| Length of stent (mm) | 26.50 (16.00, 40.00) | 30.00 (20.00, 50.00) | < 0.001 |
| TyG index | 8.80 (8.45, 9.20) | 8.90 (8.55, 9.34) | < 0.001 |
| TyG tertiles | 0.001 | ||
| T1, n (%) | 316 (67.67) | 151 (32.33) | |
| T2, n (%) | 279 (59.87) | 187 (40.13) | |
| T3, n (%) | 271 (56.34) | 210 (43.66) | |
ACEI angiotensin-converting enzyme inhibitor, ARBs angiotensin receptor blockers, BMI body mass index, CAD coronary artery disease, DAPT dual antiplatelet therapy, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HDL-C high-density lipoprotein-cholesterol, HbA1c glycated hemoglobin A1c, hs-CRP hypersensitive C-reactive protein, LVEF left ventricular ejection fraction, LDL-C low-density lipoprotein-cholesterol, MI myocardial infarction, NT-proBNP N-terminal pro-B-type natriuretic peptide, PCI percutaneous coronary intervention, PAD peripheral arterial disease, Pcr plasma creatine, TC total cholesterol, TyG triglyceride-glucose